NurExone Reports 2024 Shareholder Meeting Voting Results

TORONTO and HAIFA, Israel, June 4, 2024 – NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90), a leader in regenerative medicine, disclosed the outcomes of its annual general and special shareholder meeting held on June 3, 2024, through a live webcast. The shareholders overwhelmingly endorsed all proposed resolutions, with more than 99% approval.

The meeting saw participation from 41 shareholders either in person or via proxy, representing 20,329,922 common shares, equivalent to 30.88% of the total 65,830,428 issued common shares as of the record date.

All director nominees listed in the company's management information circular dated April 19, 2024, were elected to serve until the subsequent annual meeting or until their successors are appointed. The election results were:

- Yoram Drucker: 20,295,986 votes for (99.97%), 5,400 votes withheld (0.03%)
- Lior Shaltiel: 20,295,986 votes for (99.97%), 5,400 votes withheld (0.03%)
- Gadi Riesenfeld: 20,300,186 votes for (99.99%), 1,200 votes withheld (0.01%)
- James (Jay) Richardson: 20,295,986 votes for (99.97%), 5,400 votes withheld (0.03%)
- Oded Orgil: 20,295,986 votes for (99.97%), 5,400 votes withheld (0.03%)

Additionally, shareholders reappointed Ziv Haft, CPA (Isr.), a BDO member firm, as the company's auditor for the upcoming year, granting the board the authority to set their compensation. An amendment to the company's omnibus equity incentive plan was approved, increasing the reserved common shares for issuance to 13,166,085, representing 20% of the outstanding shares as of the record date. Shareholders also authorized the company's continuance from the Province of Alberta to the Province of Ontario. The voting results were as follows:

- Reappointment of Auditor: 20,328,509 votes for (99.99%), 1,412 votes withheld (0.01%)
- Approval of Equity Incentive Plan Amendment: 20,227,974 votes for (99.64%), 73,412 votes against (0.36%)
- Approval of Continuance: 20,299,386 votes for (99.99%), 2,000 votes against (0.01%)

The company expressed gratitude to all participating shareholders.

NurExone also announced the allocation of stock options and restricted share units under the Equity Incentive Plan. In total, 1,815,900 stock options and 2,000,000 restricted share units were granted to select officers, directors, employees, and consultants. Each stock option is exercisable at $0.51 per share for ten years, with 580,000 options vesting quarterly over one year and the remaining 1,235,900 options vesting over two years. Each restricted share unit will vest on the one-year anniversary and convert into a common share. These awards are subject to the TSX Venture Exchange's hold period policies.

NurExone Biologic Inc., listed on TSXV, is developing a platform for exosome-based therapies aimed at treating Central Nervous System injuries non-invasively. Its leading product, ExoPTEN for acute spinal cord injury, has shown a 75% motor function recovery rate in laboratory rats when administered intranasally. ExoPTEN has received Orphan Drug Designation from the FDA. The company's technology offers new drug delivery solutions for other medical needs.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!